

1 **Percentage of Foveal versus Total Macular Geographic Atrophy as a Predictor of Visual**
2 **Acuity in Age-related Macular Degeneration**

3
4 Bagheri, Saghar, M.D.¹, Lains, Ines, M.D.¹, Silverman, Rebecca, cand. med.¹, Kim, Ivana, M.D.¹,
5 Elliott, Dean, M.D.¹, Silva, Rufino, MD., PhD, FEBO², Miller, John, M.D.¹, Husain, Deeba, M.D.¹,
6 Miller, Joan W, M.D.¹, Saad, Leonide, Ph.D.^{3,4}, Vavvas, Demetrios, M.D., Ph.D.¹

7
8 ¹Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA,
9 United States.

10 ²Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC); Faculty of
11 Medicine, University of Coimbra (FMUC), and Association for Innovation and Biomedical Research
12 on Light and Image (AIBILI), Coimbra, Portugal.

13 ³ Harkness Eye Institute, Columbia University Medical Center, New York, NY, United States.

14 ⁴Alkeus Pharmaceuticals, Boston, MA, United States.

15
16 **Meeting Presentation:** This paper was presented in part as a paper presentation at the 2017
17 Annual Meeting of the Association for Research in Vision and Ophthalmology; May 9, 2017;
18 Baltimore, Maryland.

19
20 **Corresponding author:**

21 Saghar Bagheri, M.D.

22 Massachusetts Eye and Ear Infirmary

23 243 Charles St,

24 Boston, MA, 02114

25 phone: +1 617-573-6874

26 fax: +1 617-573-3011

27 email: Saghar_bagheri@meei.harvard.edu

28
29 **Running title:** Percentage of Foveal Geographic Atrophy as a Predictor of Visual Acuity

30 **Word count:** 1951

31 **Conflict of Interest:** The authors declare no conflict of interest.

32 **Financial support:** None related to this study.

33

34 **Abstract**

35

36 **Objectives:** To investigate the relationship between visual acuity (VA), total area of geographic
37 atrophy (GA) and percentage of foveal GA.

38 **Methods:** Multicenter, retrospective cross-sectional study of patients with GA due to age-related
39 macular degeneration. Demographics, VA, fundus autofluorescence (FAF) and optical coherence
40 tomography (OCT) images were collected. Using FAF images aided by OCT, foveal sparing status,
41 GA pattern, total GA size, and percentage of GA covering the foveal area - area within a 1.5 mm
42 diameter circle centered on the fovea centralis - were assessed. Univariable and multiple linear
43 regression analyses were performed.

44 **Results:** 54 eyes (mean age 78.7 ± 7.7 (SD), 60.0% female) were studied. Mean VA was 0.8 ± 0.6
45 logMAR, mean total GA 8.8 ± 6.7 mm² and mean percentage of foveal GA was $71.5 \pm 30.9\%$. Of all
46 assessed eyes, 48.2% (n = 26) presented with multifocal GA, and 18.5% (n = 10) had foveal sparing.
47 Multiple regression analysis revealed that, controlling for age and GA pattern, the percentage of
48 foveal GA presented a statistically significant association with VA ($\beta = 0.41$, $P = 0.004$). No
49 significant associations were observed with mean total GA size, while controlling for the same
50 variables ($\beta = 0.010$, $P = 0.440$).

51 **Conclusion:** Percentage of foveal GA was significantly associated with VA impairment, while the
52 same was not verified for total GA area. These findings suggest that percentage of foveal GA may
53 represent a more useful tool for assessing the impact of GA on VA. Further validation is needed in
54 larger cohorts.

55

56

57 INTRODUCTION

58 Age-related macular degeneration (AMD) is the leading cause of visual disability in elderly patients in
59 industrialized countries.¹ Geographic Atrophy (GA) represents the late stage of dry AMD, and it is
60 characterized by the irreversible loss of macular retinal tissue, retinal pigment epithelium (RPE), and
61 choriocapillaris.² Although this process occurs in a slowly progressive way, it causes decreases in
62 central vision over time³, which rapidly accelerates when GA covers the foveal center. GA is
63 responsible for severe vision loss in approximately 20% of all patients with AMD, may affect up to
64 22% of the population in 90-year-old people²⁻⁴, and more than 8 million people are affected
65 worldwide^{2, 4}. For not well understood reasons, atrophic macular diseases such as GA due to dry
66 AMD can spare the foveal center until late in the disease course and the so called foveal sparing has
67 been reported in about 20% of representative GA populations enrolled in clinical trials⁵.

68

69 Color fundus photography, fundus autofluorescence (FAF) and optical coherence tomography (OCT)
70 imaging can be used to identify and follow GA lesions. However, FAF is considered by most to be
71 the imaging of choice that allows for a sharp discrimination of a lesion's boundaries. This is primarily
72 because FAF provides a good visualization of the high contrast between atrophic (hypofluorescent)
73 and normal areas^{4, 6}. On OCT, GA is typically characterized^{4, 6} by the presence of thinning of the
74 hyperreflective external bands due to attenuation/loss of the photoreceptors, ellipsoid zone and
75 retinal pigment epithelium (RPE)/Bruch's complex; as well as the presence of deeper hyper-
76 reflectivity in the sub-RPE layers due to increased laser light penetration through the atrophic RPE².
77 The total area of GA lesions is often used as an indicator of severity in late-stage dry AMD. However,
78 this measure does not readily predict residual visual acuity (VA) nor VA decline rates⁷. Foveal
79 sparing status has been shown to correlate better with VA than total GA size, nevertheless, its binary
80 nature prevents it from being used to quantify the continuous shrinking of the spared foveal area and
81 the worsening of VA over time⁸.

82

83 To explore more sensitive anatomical predictors of VA in GA, we defined and analyzed the
84 percentage of foveal GA and its association with VA. This may lead to more accurate outcome

85 measures for clinical trials as well as for patient counseling.

86

87 **METHODS**

88 **▪ Study Design**

89 This study is a multicenter, retrospective cross-sectional study. The research protocol was
90 conducted in accordance with Health Insurance Portability and Accountability Act requirements and
91 the tenets of the Declaration of Helsinki. The Institutional Review Boards of MEE and of the Coimbra
92 University Hospital approved this study.

93

94 **▪ Study Population and Study Protocol**

95 We identified and retrospectively reviewed the medical records and images of eyes with GA. We
96 adopted the most recent AREDS definitions⁹, namely that geographic atrophy is present if the lesion
97 has a diameter of 433 μm or more (AREDS circle I-2) and has at least 2 of the following features:
98 absence of retinal pigment epithelium (RPE) pigment, circular shape, or sharp margins.

99

100 Subjects from two centers were considered. At MEE, we identified patients seen between September
101 2011 to June 2017 as part of the AMD biomarkers study and from the attending clinic (DGV). From
102 Portugal, we considered subjects participating in the AMD biomarkers study, developed by the
103 Faculty of Medicine, University of Coimbra, in collaboration with the Association for Innovation and
104 Biomedical Research on Light and Image (AIBILI) and the “Centro Hospitalar e Universitário de
105 Coimbra”, Coimbra, Portugal.

106

107 For all considered subjects, exclusion criteria included: GA with CNVM; diagnosis of any other
108 vitreoretinal disease, active uveitis or ocular infection; significant media opacities that precluded the
109 observation of the ocular fundus; refractive error equal to or greater than 6 diopters of spherical
110 equivalent; history of any ocular surgery or intra-ocular procedure such as laser or intravitreal
111 injections within 90 days prior to enrollment; and diagnosis of diabetes mellitus. Additionally, only

112 eyes with both FAF and OCT images according to a predefined protocol, available on at least one
113 visit were considered for this study. For FAF, we considered eyes with high resolution 30° FAF,
114 centered on the fovea. For OCT, we used high resolution 30° spectral domain optical coherence
115 tomography (SD-OCT).

116

117 For the final included eyes, we reviewed medical records and collected the following information:
118 age, gender, smoking status, AREDS supplementation and Snellen VA at the same date of the
119 considered images.

120

121 • **Imaging analysis**

122 We reviewed FAF and OCT images of the eyes considered for this study. The fovea was defined by
123 a 1.5 mm diameter circle area of 1.77 mm², centered on the fovea centralis (Figure 1). Using the
124 Heidelberg built-in calipers, two masked graders (S.B., R.S.) independently measured the total GA
125 area and the percentage of the foveal area covered by GA on the FAF images. The same graders
126 also assessed foveal sparing status. For this grading process, OCT images were used in parallel to
127 help determine the location of the umbo/fovea centralis and the GA areas in a multimodal
128 approach¹⁰. For analysis, average values of the two graders were used, except when values
129 disagreed by more than 10%, in which case a third grader (I.L.) was used for adjudication.
130 Furthermore, we graded for foveal sparing status and GA pattern (focal or multifocal) in addition to
131 collecting demographic information on age, gender, study eye, smoking status and AREDS
132 supplementation.

133

134 • **Statistical and Data Analysis**

135 Traditional descriptive methods such as mean and standard deviation for continuous variables, and
136 percentages for dichotomous/categorical variables were used to describe the clinical and
137 demographic characteristics of the study population.

138

139 Regarding the inclusion of two eyes of the same patient for some cases, our statistical assessments
140 were performed using multilevel mixed effect models. By definition, these models are appropriate for
141 research designs in which data for participants are organized at more than 1 level (ie, nested data).
142 In this study, the units of analysis were considered the eyes (at a lower level), which are nested
143 within patients that represent the contextual/aggregate units (at a higher level)¹¹.

144

145 Univariate analyses were initially performed for all the potential confounders such as age and GA
146 pattern, and all variables with a P value ≤ 0.250 were included in the initial multiple model. A
147 backwards elimination procedure was then performed to achieve the multivariable models presented.
148 For both univariate and multivariate analyses, we report P values and beta coefficients. The beta
149 coefficients represent the change in the outcome variable for 1 unit of change in the predictor
150 variable (while holding other predictors in the model constant, in the case of multivariate analyses)¹².

151 This means, for example, given a continuous variable such as age, beta coefficients represent the
152 change in visual acuity per year increase in age. For binomial variables, such as smoking, AREDS
153 supplementation or foveal sparing, their absence was considered the reference term, so beta
154 coefficients refer to the change in their presence. The reference terms for study eye was the right
155 eye, for GA pattern unifocal GA and for gender was the female gender.

156

157 All statistics were performed using Stata version 14.1 (StataCorp LP, College Station, Texas, USA)
158 and P values < 0.05 were considered statistically significant.

159

160 **RESULTS**

161 • **Study Population**

162 We included 54 eyes from 35 patients (mean age 78.7 ± 7.7 years, 60.0% female ($n = 21$)) with GA
163 due to non-neovascular AMD. Mean VA was 0.81 (20/129 Snellen eq.) ± 0.63 [range, 0 to 2.60]
164 logMAR, mean total GA 8.79 ± 6.66 [0.84-25.36] mm^2 , mean percentage of foveal GA was $71.53 \pm$
165 30.94 [0-100] %. 48.15 % ($n = 26$) of assessed eyes presented with multifocal GA, and 18.52% ($n =$
166 10) had foveal sparing (see demographics in Table 1).

167

168 In all eyes, SD-OCT images allowed a clear identification of the umbo/fovea centralis as well as the

169 GA lesion borders. Figure 1 presents an example of measurement of percentage of foveal GA.

170 The results of the univariate analysis considering all variables of interest and their association with

171 VA is shown in Table 2.

172 • **Percentage of foveal GA**

173 The mean percentage of foveal GA was statistically significantly associated with VA in univariate

174 analysis ($\beta = 0.54$, $P < 0.001$) (Table 2). This association remained significant on multivariate

175 analysis, controlling for age and GA pattern ($\beta = 0.41$, $P = 0.004$).

176 • **Total macular GA**

177 Univariate or multivariate analysis for total macular GA revealed that there were no statistically

178 significant associations with VA ($\beta = 0.02$, $P = 0.054$, for univariate), ($\beta = 0.010$, $P = 0.440$ for

179 multivariate).

180 • **GA pattern & Foveal Sparing**

181 GA pattern presented a statistically significant association with VA ($\beta = -0.5071879$, $P = 0.001$) and

182 so did foveal sparing ($\beta = -0.5392127$, $P = 0.009$).

183

184 **DISCUSSION**

185 We present a retrospective, cross-sectional study of 54 eyes diagnosed with GA due to non-

186 neovascular AMD, in which we used FAF and SD-OCT to examine the associations of percentage of

187 foveal GA and total macular GA lesion size with VA. Our results revealed that, after accounting for

188 potential confounders such as age and GA pattern, the percentage of foveal GA was significantly

189 associated with VA, while the same was not observed for total GA lesion size.

190

191 In GA clinical studies, the most common outcome measures for GA are changes in total GA,

192 changes in square root GA, or other phenotypic refinements^{13, 14}. As our results show, total GA

193 poorly correlates with VA, and potentially patients' overall quality of life. This finding is in agreement

194 with previously published literature, which showed no relationship of total GA size with VA and has
195 been investigated by multiple groups^{8, 15}.

196

197 Efforts have been made to study the association between VA and the distance between the edges of
198 GA and the fovea^{15, 16}, or to examine residual visual function in the presence of foveal sparing
199 lesions¹⁵⁻¹⁷. Foveal sparing status has been shown to have a stronger correlation with VA than total
200 GA size, however, it does not quantify the extent to which the foveal area is affected nor the
201 worsening of VA over time since it only measures presence or absence of geographic atrophy in the
202 anatomic foveola centralis^{8, 15, 16}. A recent investigation of the associations of VA with total GA size
203 as well as foveal sparing status in 65 eyes found no relationship between VA and total GA size as
204 well as foveal island size¹⁸. The same group also evaluated the width of the bridge - defined as the
205 minimal linear dimension of intact RPE located within the residual foveal island - and only found a
206 suggestion of a positive relationship in the range of 300 to 550 μm of bridge width and no
207 relationship at all outside of this range leading to the conclusion that this measurement might not be
208 an ideal outcome parameter for GA clinical trials.

209

210 Our study results suggest that using the percentage of foveal GA is potentially a more sensitive
211 outcome parameter for association with visual acuity. Our study however, is limited by its modest
212 size and retrospective design. As such, our results should be validated in larger, more representative
213 populations, before changes in percentage of foveal GA can be used more widely in clinical trials or
214 clinical practice. Further studies should examine more precise evaluation of affected areas as well as
215 evaluate the progression rate of percentage of foveal GA over time and examine predictive ability of
216 such tool on future VA changes.

217

218 In conclusion, here we propose for the first time the use of percentage of foveal GA as a possible
219 predictor of VA in GA. Our data suggests that such a measure may have a stronger association with
220 VA impairment than total GA size. Therefore, with future research, it might represent a better tool to
221 measure VA decline over time compared to the foveal sparing status.

222 **Acknowledgments:** None.

223 **Conflict of Interest:** The authors declare no conflict of interest.

224 **Funding:** None related to this study.

225 **Ethical Approval:** The research protocol was conducted in accordance with Health Insurance

226 Portability and Accountability Act requirements and the tenets of the Declaration of Helsinki. The

227 Institutional Review Boards of MEE and of the Coimbra University Hospital approved this study.

228 **REFERENCES**

- 229 1. Miller JW, Bagheri S, Vavvas DG. Advances in Age-related Macular Degeneration
230 Understanding and Therapy. *US Ophthalmic Rev* 2017; **10**(2): 119-130.
231
- 232 2. Sacconi R, Corbelli E, Querques L, Bandello F, Querques G. A Review of Current
233 and Future Management of Geographic Atrophy. *Ophthalmol Ther* 2017; **6**(1):
234 69-77.
235
- 236 3. Schmitz-Valckenberg S, Sahel JA, Danis R, Fleckenstein M, Jaffe GJ, Wolf S *et al.*
237 Natural History of Geographic Atrophy Progression Secondary to Age-Related
238 Macular Degeneration (Geographic Atrophy Progression Study). *Ophthalmology*
239 2016; **123**(2): 361-368.
240
- 241 4. Sunness JS, Margalit E, Srikumaran D, Applegate CA, Tian Y, Perry D *et al.* The
242 long-term natural history of geographic atrophy from age-related macular
243 degeneration: enlargement of atrophy and implications for interventional
244 clinical trials. *Ophthalmology* 2007; **114**(2): 271-277.
245
- 246 5. Retinal Physician. Reading and Macular Disease - available at
247 [https://www.retinalphysician.com/issues/2009/september-2009/reading-](https://www.retinalphysician.com/issues/2009/september-2009/reading-and-macular-disease)
248 [and-macular-disease](https://www.retinalphysician.com/issues/2009/september-2009/reading-and-macular-disease). (Accessed: 26th April 2018). *Retinal Physician* 2009.
249
- 250 6. Domalpally A, Danis R, Agron E, Blodi B, Clemons T, Chew E *et al.* Evaluation of
251 Geographic Atrophy from Color Photographs and Fundus Autofluorescence
252 Images: Age-Related Eye Disease Study 2 Report Number 11. *Ophthalmology*
253 2016; **123**(11): 2401-2407.
254
- 255 7. Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian Y, Hawkins B *et*
256 *al.* Enlargement of atrophy and visual acuity loss in the geographic atrophy form
257 of age-related macular degeneration. *Ophthalmology* 1999; **106**(9): 1768-1779.
258
- 259 8. Sunness JS, Rubin GS, Zuckerbrod A, Applegate CA. Foveal-Sparing Scotomas in
260 Advanced Dry Age-Related Macular Degeneration. *J Vis Impair Blind* 2008;
261 **102**(10): 600-610.
262
- 263 9. Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP *et*
264 *al.* Methods and reproducibility of grading optimized digital color fundus
265 photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number
266 2). *Invest Ophthalmol Vis Sci* 2013; **54**(7): 4548-4554.
267
- 268 10. Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O *et al.* Regression of
269 choroidal neovascularization results in macular atrophy in anti-vascular
270 endothelial growth factor-treated eyes. *Am J Ophthalmol* 2015; **159**(1): 9-19
271 e11-12.

- 272
273 11. Burton P, Gurrin L, Sly P. Extending the simple linear regression model to
274 account for correlated responses: an introduction to generalized estimating
275 equations and multi-level mixed modelling. *Stat Med* 1998; **17**(11): 1261-1291.
276
- 277 12. Applied Longitudinal Analysis, 2nd Edition. Available at:
278 [https://www.wiley.com/en-](https://www.wiley.com/en-us/Applied+Longitudinal+Analysis%2C+2nd+Edition-p-9780470380277)
279 [us/Applied+Longitudinal+Analysis%2C+2nd+Edition-p-9780470380277](https://www.wiley.com/en-us/Applied+Longitudinal+Analysis%2C+2nd+Edition-p-9780470380277).
280 (Accessed: 1st April 2018). *Wiley*.
281
- 282 13. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HP, Schmitz-
283 Valckenberg S *et al*. Progression of geographic atrophy and impact of fundus
284 autofluorescence patterns in age-related macular degeneration. *Am J*
285 *Ophthalmol* 2007; **143**(3): 463-472.
286
- 287 14. Feuer WJ, Yehoshua Z, Gregori G, Penha FM, Chew EY, Ferris FL *et al*. Square
288 root transformation of geographic atrophy area measurements to eliminate
289 dependence of growth rates on baseline lesion measurements: a reanalysis of
290 age-related eye disease study report no. 26. *JAMA Ophthalmol* 2013; **131**(1):
291 110-111.
292
- 293 15. Lindner M, Boker A, Mauschitz MM, Gobel AP, Fimmers R, Brinkmann CK *et al*.
294 Directional Kinetics of Geographic Atrophy Progression in Age-Related Macular
295 Degeneration with Foveal Sparing. *Ophthalmology* 2015; **122**(7): 1356-1365.
296
- 297 16. Schmitz-Valckenberg S, Nadal J, Fimmers R, Lindner M, Holz FG, Schmid M *et al*.
298 Modeling Visual Acuity in Geographic Atrophy Secondary to Age-Related
299 Macular Degeneration. *Ophthalmologica* 2016; **235**(4): 215-224.
300
- 301 17. Hart WM, Jr., Burde RM. Three-dimensional topography of the central visual
302 field. Sparing of foveal sensitivity in macular disease. *Ophthalmology* 1983;
303 **90**(8): 1028-1038.
304
- 305 18. Lindner M, Nadal J, Mauschitz MM, Luning A, Czauderna J, Pfau M *et al*.
306 Combined Fundus Autofluorescence and Near Infrared Reflectance as
307 Prognostic Biomarkers for Visual Acuity in Foveal-Sparing Geographic Atrophy.
308 *Invest Ophthalmol Vis Sci* 2017; **58**(6): BIO61-BIO67.
309
310
311
312

313 **Titles and legends to figures**

314

315 **Figure 1. Percentage of foveal geographic atrophy (GA)**

316 Representative blue autofluorescence fundus image outlining geographic atrophy (GA) within the
317 foveal area, defined by a 1.5 mm diameter circle centered on the fovea centralis which has been
318 determined with the use of optical coherence tomography (OCT) images.

319

320

Table 1. Demographic and Clinical Characteristics of the Included Study Eyes

Age at date of imaging in years (n=54)	
Mean \pm SD (range)	78.7 \pm 7.7 (62 to 96)
Gender (n=35)	
Female	21 (60.0%)
Male	14 (40.0%)
Smoking (n=30)	
no	27 (90.0%)
yes	3 (10.0%)
AREDS (n=38)	
no	14 (36.8%)
yes	24 (63.2%)
Study Eye (n=54)	
OD	29 (53.7%)
OS	25 (46.3%)
GA pattern (n=54)	
unifocal	28 (51.9%)
multifocal	26 (48.2%)
Foveal Sparing (n=54)	
no	44 (81.5%)
yes	10 (18.5%)
VA in logmar (n=54)	
Mean \pm SD (range)	0.8 \pm 0.6 (0 to 2.6)

GA = Geographic Atrophy; VA = Visual Acuity.

321

322

323

324

325

326

327

Table 2. Univariable Linear Regression Analysis Considering VA as the Outcome

	β	<i>P</i> value	95% CI
Age, years	0.017	0.113	[-0.00409, 0.038529]
Gender ^a	-0.285	0.097	[-0.6215504, 0.0512273]
Study Eye ^b	-0.226	0.178	[-0.5543471, -0.102713]
Smoking ^c	-0.319	0.398	[-1.058263, 0.4205226]
AREDS ^c	-0.412	0.051	[-0.8265572, -0.0018414]
GA pattern ^d	-0.507	0.001*	[-0.8118193, -0.2025564]
Foveal sparing ^c	-0.539	0.009*	[-0.9440415, -0.134384]
Total GA (mm ²)	0.024	0.054	[-0.0004198, 0.048712]
% of foveal GA	0.536	0.000*	[0.2625702, 0.8104187]

VA = Visual Acuity; CI = confidence interval; GA = Geographic Atrophy.

*P*values < 0.05 are noted by an asterisk.


^a Female gender considered the reference term.

^b Right eye considered the reference term.

^c Reference term considered as the absence of these variables.

^d Unifocal Geographic Atrophy considered the reference term.

GA within the fovea
 $0.66\text{mm}^2 = 37\%$



Foveal Area
 1.77mm^2